Peptides Similar to CT-388

Peptides Related to CT-388#

CT-388 occupies a unique position among dual GLP-1/GIP agonists due to its signal-biased mechanism. While several other dual-receptor agonists are in development, CT-388 is the only one characterized as having minimal beta-arrestin recruitment at both receptors. Its 22.5% weight loss at 48 weeks in Phase 2 is among the highest reported for dual GLP-1/GIP agonists.

Tirzepatide (Mounjaro/Zepbound)#

Tirzepatide is the most direct comparator as the only approved dual GLP-1/GIP agonist:

CT-388's 22.5% weight loss at 48 weeks compares favorably with tirzepatide's 20.9% at 72 weeks, though the different trial designs (Phase 2 vs Phase 3, different populations) limit direct comparison.

VK2735 (Viking Therapeutics)#

VK2735 is another dual GLP-1/GIP agonist:

• VK2735 is further in development (Phase 3 vs Phase 2)
• VK2735 has both SC and oral formulations; CT-388 is SC only
• VK2735 Phase 2 (13 weeks) showed 14.7% weight loss; CT-388 Phase 2 (48 weeks) showed 22.5%
• Different trial durations make comparison difficult

Semaglutide (Wegovy)#

CT-388 offers potential advantages over selective GLP-1 agonism:

• Dual GLP-1/GIP mechanism with biased signaling
• 22.5% weight loss versus semaglutide's ~15-17% at similar timepoints
• Semaglutide has extensive long-term safety and CV outcomes data that CT-388 lacks

Retatrutide (Eli Lilly)#

Retatrutide's triple agonism provides the highest reported weight loss:

• ~24.2% weight loss in Phase 2 (48 weeks) versus CT-388's 22.5% (48 weeks)
• Glucagon receptor activity provides additional hepatic benefits
• Both are in Phase 2, with Phase 3 planned

Summary Comparison#

Comparison Context#

CT-388 belongs to the Metabolic category of research peptides. Comparing CT-388 with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.

Detailed Comparisons#

The following peptides and compounds are most closely related to CT-388 in mechanism, indication, or therapeutic category:

CT-388 vs Tirzepatide#

Similarity: Very High - Both are dual GLP-1/GIP receptor agonists administered as once-weekly SC injections for obesity

Key Differences: CT-388 is signal-biased (minimal beta-arrestin recruitment); tirzepatide is a GIP-biased balanced agonist. CT-388 showed 22.5% weight loss at 48 weeks (Phase 2); tirzepatide showed 20.9% at 72 weeks (Phase 3). Tirzepatide is FDA-approved; CT-388 is in Phase 2.

Advantages of Tirzepatide: Signal-biased mechanism may reduce receptor desensitization, higher Phase 2 weight loss in shorter timeframe, potential MASH benefits

Disadvantages of Tirzepatide: Not approved (tirzepatide is approved), much smaller evidence base, no head-to-head data, no CV outcomes data, earlier development stage

Researchers choosing between CT-388 and Tirzepatide should consider the development stage, available evidence, and specific research objectives when making their selection.

CT-388 vs VK2735#

Similarity: High - Both are dual GLP-1/GIP agonists in clinical development for obesity

Key Differences: CT-388 is signal-biased; VK2735's signaling profile is not disclosed. CT-388 has 48-week Phase 2 data; VK2735 has 13-week Phase 2 data. VK2735 has both SC and oral formulations; CT-388 is SC only.

Advantages of VK2735: Higher weight loss (22.5% at 48wk vs 14.7% at 13wk), novel biased mechanism, longer Phase 2 duration

Disadvantages of VK2735: Less advanced development (Phase 2 vs Phase 3 for VK2735), no oral formulation, different trial durations limit comparison

Researchers choosing between CT-388 and VK2735 should consider the development stage, available evidence, and specific research objectives when making their selection.

CT-388 vs Semaglutide#

Similarity: High - Both are GLP-1 receptor agonists; CT-388 adds GIP receptor activation with signal-biased profile

Key Differences: Semaglutide is a selective GLP-1 agonist; CT-388 is a signal-biased dual GLP-1/GIP agonist. Semaglutide is FDA-approved with extensive safety and CV outcomes data.

Advantages of Semaglutide: Dual GLP-1/GIP mechanism with biased signaling, higher weight loss (22.5% vs ~15-17% for semaglutide), potential MASH benefits

Disadvantages of Semaglutide: Not approved, smaller evidence base, no CV outcomes data, no oral formulation (semaglutide has oral Rybelsus)

Researchers choosing between CT-388 and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.

CT-388 vs Retatrutide#

Similarity: Moderate - Both are next-generation multi-receptor obesity therapies with different receptor targets

Key Differences: Retatrutide is a triple agonist (GIP + GLP-1 + glucagon); CT-388 is a signal-biased dual agonist (GLP-1 + GIP). Retatrutide showed ~24.2% weight loss in Phase 2 (48 weeks). Different third mechanism (glucagon vs biased signaling).

Advantages of Retatrutide: Signal-biased mechanism may reduce desensitization, potentially better tolerability profile

Disadvantages of Retatrutide: Lower peak weight loss (22.5% vs ~24.2%), no glucagon receptor activity for hepatic fat oxidation, both in Phase 2

Researchers choosing between CT-388 and Retatrutide should consider the development stage, available evidence, and specific research objectives when making their selection.

CT-388 vs CagriSema#

Similarity: Moderate - Both achieve approximately 20%+ weight loss through dual- mechanism approaches targeting different receptor combinations

Key Differences: CagriSema targets amylin + GLP-1 as a two-peptide combination; CT-388 targets GLP-1 + GIP with biased signaling as a single molecule. CagriSema has Phase 3 data and NDA filed.

Advantages of CagriSema: Single molecule (simpler than two-peptide combination), signal-biased mechanism, higher weight loss (22.5% vs 20.4%)

Disadvantages of CagriSema: Much earlier development stage (Phase 2 vs NDA filed), smaller evidence base, no active comparator data

Researchers choosing between CT-388 and CagriSema should consider the development stage, available evidence, and specific research objectives when making their selection.

Related Reading#

• CT-388 overview and research guide
• CT-388 research evidence
• CT-388 dosing protocols